Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...

Despite advancements in early detection and innovative treatments, Black women in the United States face higher mortality ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

The FDA has approved Rybrevant in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ...

The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

Discover AstraZeneca's groundbreaking patent for dual-target antibody molecules aimed at EGFR and c-Met, paving the way for innovative cancer therapies.

The stock is trading above its 5-day, 10-day, 20-day, 30-day, 50-day, 100-day, 150-day, and 200-day simple moving averages ...

This surge came after the company announced approval to import and distribute Durvalumab (Imfinzi) infusion in two dosages.

Results have been positive, with SHR-1701 demonstrating improvements in overall survival, but taking market share will be a ...

One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.

(RTTNews) - Black Diamond Therapeutics, Inc. (BDTX) announced positive initial Phase 2 results for BDTX-1535 in patients with relapsed or refractory non-small cell lung cancer also known as NSCLC, ...

Proto-oncogenes regulate cell growth; mutations convert them to oncogenes, leading to cancer by disrupting normal cell ...